Literature DB >> 15857801

Drug resistant Plasmodium falciparum in an area of seasonal transmission.

Hamza A Babiker1, Gwiria Satti, Heather Ferguson, Riad Bayoumi, David Walliker.   

Abstract

Eastern Sudan lies at the edge of the malaria endemicity stratum, where transmission intensity is low and seasonal. The main malaria parasite in the region, Plasmodium falciparum, survives the long dry and transmission-free season as asymptomatic sub-patent infections, and resurges following annual rains. The short-lived annual transmission in this area precipitates cyclical malaria epidemics among the semi-immune inhabitants who resort to excessive anti-malarial drugs usage at this time of the year. Chloroquine resistance (CQR) first emerged in this area in the mid 1980s; however, subsequent surveys demonstrated that the rate of parasitological failure to CQ remained stable over a period of 8 years (1986-1993). Nevertheless, the CQR level varied between years in association with the amount of annual rain. Detailed molecular surveys revealed significant temporal fluctuations in the frequency of resistant P. falciparum genotypes, increasing during the dry season but dwindling at the start of the next transmission season. The pattern of spread of drug resistance in the area is discussed in the context of parasite biology and malaria epidemiology of this region.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15857801     DOI: 10.1016/j.actatropica.2005.04.007

Source DB:  PubMed          Journal:  Acta Trop        ISSN: 0001-706X            Impact factor:   3.112


  13 in total

1.  Comparison of a SYBR green I-based assay with a histidine-rich protein II enzyme-linked immunosorbent assay for in vitro antimalarial drug efficacy testing and application to clinical isolates.

Authors:  David J Bacon; Christine Latour; Carmen Lucas; Olga Colina; Pascal Ringwald; Stéphane Picot
Journal:  Antimicrob Agents Chemother       Date:  2007-01-12       Impact factor: 5.191

2.  Rational deployment of antimalarial drugs in Africa: should first-line combination drugs be reserved for paediatric malaria cases?

Authors:  Colin J Sutherland; Hamza Babiker; Margaret J Mackinnon; Lisa Ranford-Cartwright; Badria Babiker El Sayed
Journal:  Parasitology       Date:  2011-08-03       Impact factor: 3.234

3.  Frequency distribution of antimalarial drug resistance alleles among Plasmodium falciparum isolates from Gezira State, central Sudan, and Gedarif State, eastern Sudan.

Authors:  Michela Menegon; Albadawi A Talha; Carlo Severini; Sayed M Elbushra; Ahmed A Mohamedani; Elfatih M Malik; Tarig A Mohamed; Walther H Wernsdorfer; Giancarlo Majori; Bakri Y M Nour
Journal:  Am J Trop Med Hyg       Date:  2010-08       Impact factor: 2.345

4.  Environmental, pharmacological and genetic influences on the spread of drug-resistant malaria.

Authors:  Tiago Antao; Ian M Hastings
Journal:  Proc Biol Sci       Date:  2010-11-17       Impact factor: 5.349

Review 5.  The dynamics of mutations associated with anti-malarial drug resistance in Plasmodium falciparum.

Authors:  Ananias A Escalante; David L Smith; Yuseob Kim
Journal:  Trends Parasitol       Date:  2009-10-26

Review 6.  Malaria resurgence: a systematic review and assessment of its causes.

Authors:  Justin M Cohen; David L Smith; Chris Cotter; Abigail Ward; Gavin Yamey; Oliver J Sabot; Bruno Moonen
Journal:  Malar J       Date:  2012-04-24       Impact factor: 2.979

7.  Transmission intensity and drug resistance in malaria population dynamics: implications for climate change.

Authors:  Yael Artzy-Randrup; David Alonso; Mercedes Pascual
Journal:  PLoS One       Date:  2010-10-26       Impact factor: 3.240

8.  Resistance of a rodent malaria parasite to a thymidylate synthase inhibitor induces an apoptotic parasite death and imposes a huge cost of fitness.

Authors:  Francis W Muregi; Isao Ohta; Uchijima Masato; Hideto Kino; Akira Ishih
Journal:  PLoS One       Date:  2011-06-16       Impact factor: 3.240

9.  Evolutionary biology and the avoidance of antimicrobial resistance.

Authors:  Andrew F Read; Silvie Huijben
Journal:  Evol Appl       Date:  2009-02       Impact factor: 5.183

10.  From chloroquine to artemisinin-based combination therapy: the Sudanese experience.

Authors:  E M Malik; T A Mohamed; K A Elmardi; R M Mowien; A H Elhassan; S B Elamin; A A Mannan; E S Ahmed
Journal:  Malar J       Date:  2006-07-31       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.